Therapy Areas: Cardiovascular
Tenaya Therapeutics Names Parschauer to Its Board of Directors
27 December 2021 - - US-based biotechnology company Tenaya Therapeutics, Inc. (NASDAQ: TNYA) has appointed Karah Parschauer, J.D., to its board of directors and of Joanna Auch as senior vice president of People and Culture, the company said.

Parschauer has nearly 20 years of relevant experience, including with biopharmaceutical companies, with proven success in corporate governance, mergers and acquisitions, and leading organizations through growth and transformation.

She currently serves as Chief Legal officer and executive vice president at Ultragenyx Pharmaceutical Inc., a global biopharmaceutical company advancing a diverse portfolio of approved therapies and product candidates including gene therapies for ultra-rare genetic diseases.

Her previous experience includes over a decade in roles of increasing responsibility at Allergan plc. Parschauer began her legal career at Latham and Watkins LLP.

She is currently a member of the board of directors for Evolus, Inc. (NASDAQ: EOLS) and Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB). Parschauer earned her B.A. from Miami University and J.D. from Harvard Law School.

Auch brings over 15 years of human resources experience across various industries, including pharmaceutical, healthcare and technology.

She most recently served as Head of Human Resources for North America at Santen, Inc., a global pharmaceutical company focused on ophthalmology, where among other responsibilities she led the human resources integration for two acquisitions.

Auch earned her B.A. from San Jose State University and is a member of CSHRP, Community for Strategic HR Partnerships. She will report to Tenaya's CEO in a newly created role leading all aspects of human resources including talent acquisition and management, culture and values, compensation and benefits and organizational effectiveness.

Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease.

Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine.


Related Headlines